Silviya Balabanova

The SANAD II study of the effectiveness and cost-effectiveness of valproate versus levetiracetam for newly diagnosed generalised and unclassifiable epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 211 citations · Full text

Medicine, Neurology, Pharmacology +17

The SANAD II study of the effectiveness and cost-effectiveness of levetiracetam, zonisamide, or lamotrigine for newly diagnosed focal epilepsy: an open-label, non-inferiority, multicentre, phase 4, randomised controlled trial

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · The Lancet · 2021 · 191 citations · Full text

Medicine, Neurology, Pharmacotherapy +15

Release of TGFβig-h3 by gastric myofibroblasts slows tumor growth and is decreased with cancer progression

Chris Holmberg, Michael Quante, Islay Steele et al. · Carcinogenesis · 2012 · 38 citations · Full text

Medicine, Cell Biology, Oncology +17

Opening research sites in multicentre clinical trials within the UK: a detailed analysis of delays

Anna Kearney, Andrew McKay, Helen Hickey et al. · BMJ Open · 2014 · 24 citations · Full text

Public Health, Biostatistics, Clinical Trial Regulation +16

Lamotrigine versus levetiracetam or zonisamide for focal epilepsy and valproate versus levetiracetam for generalised and unclassified epilepsy: two SANAD II non-inferiority RCTs

Anthony G Marson, Girvan Burnside, Richard Appleton et al. · Health Technology Assessment · 2021 · 22 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14